Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Serum endocan, Serum copeptin.
- Who it may be relevant to
- Registry conditions: Endocan, Copeptin, Serum, Preterm Neonates. Basic parameters: 28 Weeks — 36 Weeks · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Overview
This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.
Detailed description
Preterm birth continues to be one of the significant challenges in perinatal medicine because of its high incidence of morbidities and mortalities. Its burden on the infant, the family, healthcare systems, and society is enormous.
Endocan is implicated in the recruitment of circulating lymphocytes to inflammatory sites and leukocyte adhesion and activation. Endocan also inhibits leukocyte-endothelial cell adhesion and reduces the excessive leukocyte recruitment into the lungs.
Copeptin, also known as the arginine vasopressin (AVP) associated glycopeptides. AVP is a vasoactive neurohypophysial hormone. It is one of the primary hormones of the hypothalamic-pituitary-adrenal axis, and its primary function is to regulate water and maintain electrolyte homeostasis. The primary stimulus for AVP release is hyperosmolarity.
Interventions
- Diagnostic test Serum endocan
Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life. - Diagnostic test Serum copeptin
Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
Primary outcome measures
- Serum endocan level for prediction of severity of respiratory distress syndrome [Time frame: First day of life]
Secondary outcome measures (3)
- Serum copeptin level for prediction of severity of respiratory distress syndrome [Time frame: 5th day of life]
- Serum endocan level for prediction of mortality [Time frame: First day of life]
- Serum copeptin level for prediction of mortality [Time frame: 5th day of life]
Eligibility criteria
Inclusion criteria
- Prematurity.
- Gestational age between 28 and 36 weeks.
- Suffering from respiratory distress syndrome.
Exclusion criteria
- Intrauterine growth restriction (IUGR).
- Hypoxic ischemic encephalopathy.
- Multiple congenital anomalies.
- Chromosomal abnormalities.
- Preterm less than 28 weeks.
- Neonates with a maternal history of chorioamnionitis (early sepsis).
- Infant of diabetic mother.
- Prelabor rupture of membranes (PROM)> 2 hours.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- Tanta University — Tanta
Identifiers
NCT: NCT07154134 · 36264PR1296/7/25